SGLT2 inhibitors and the changing landscape for treatment of diabetes

Shuangbo Liu,1 Anna Lam,2 Arslan Wazir,1 Asim N Cheema11Terrence Donnelly Heart Centre, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada; 2Division of Endocrinology, University of Alberta, Edmonton, Alberta, CanadaAbstract: Type 2 diabetes mellitus has become an epide...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liu S, Lam A, Wazir A, Cheema AN
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	diabetes empagliflozin SGLT2 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/6d6b83cb2f074f5bbf94386e9a47467a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6d6b83cb2f074f5bbf94386e9a47467a
record_format	dspace
spelling	oai:doaj.org-article:6d6b83cb2f074f5bbf94386e9a47467a2021-12-02T11:44:16ZSGLT2 inhibitors and the changing landscape for treatment of diabetes1178-203Xhttps://doaj.org/article/6d6b83cb2f074f5bbf94386e9a47467a2019-07-01T00:00:00Zhttps://www.dovepress.com/sglt2-inhibitors-and-the-changing-landscape-for-treatment-of-diabetes-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XShuangbo Liu,1 Anna Lam,2 Arslan Wazir,1 Asim N Cheema11Terrence Donnelly Heart Centre, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada; 2Division of Endocrinology, University of Alberta, Edmonton, Alberta, CanadaAbstract: Type 2 diabetes mellitus has become an epidemic with rapidly increasing prevalence worldwide. While strict glycemic control has been shown to reduce the risk of diabetic microvascular complications, its role in preventing cardiovascular disease has been less clear. Indeed, anti-hyperglycemic therapies have historically been neutral for cardiovascular benefit. However, recent cardiovascular outcome trials utilizing sodium glucose transporter 2 inhibitors across a broad spectrum of cardiovascular disease patients have demonstrated significant mortality benefit resulting in a paradigm shift in the approach towards patients with heart disease and diabetes mellitus.Keywords: diabetes, empagliflozin, SGLT2Liu SLam AWazir ACheema ANDove Medical PressarticlediabetesempagliflozinSGLT2Therapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 15, Pp 861-867 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetes empagliflozin SGLT2 Therapeutics. Pharmacology RM1-950
spellingShingle	diabetes empagliflozin SGLT2 Therapeutics. Pharmacology RM1-950 Liu S Lam A Wazir A Cheema AN SGLT2 inhibitors and the changing landscape for treatment of diabetes
description	Shuangbo Liu,1 Anna Lam,2 Arslan Wazir,1 Asim N Cheema11Terrence Donnelly Heart Centre, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada; 2Division of Endocrinology, University of Alberta, Edmonton, Alberta, CanadaAbstract: Type 2 diabetes mellitus has become an epidemic with rapidly increasing prevalence worldwide. While strict glycemic control has been shown to reduce the risk of diabetic microvascular complications, its role in preventing cardiovascular disease has been less clear. Indeed, anti-hyperglycemic therapies have historically been neutral for cardiovascular benefit. However, recent cardiovascular outcome trials utilizing sodium glucose transporter 2 inhibitors across a broad spectrum of cardiovascular disease patients have demonstrated significant mortality benefit resulting in a paradigm shift in the approach towards patients with heart disease and diabetes mellitus.Keywords: diabetes, empagliflozin, SGLT2
format	article
author	Liu S Lam A Wazir A Cheema AN
author_facet	Liu S Lam A Wazir A Cheema AN
author_sort	Liu S
title	SGLT2 inhibitors and the changing landscape for treatment of diabetes
title_short	SGLT2 inhibitors and the changing landscape for treatment of diabetes
title_full	SGLT2 inhibitors and the changing landscape for treatment of diabetes
title_fullStr	SGLT2 inhibitors and the changing landscape for treatment of diabetes
title_full_unstemmed	SGLT2 inhibitors and the changing landscape for treatment of diabetes
title_sort	sglt2 inhibitors and the changing landscape for treatment of diabetes
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/6d6b83cb2f074f5bbf94386e9a47467a
work_keys_str_mv	AT lius sglt2inhibitorsandthechanginglandscapefortreatmentofdiabetes AT lama sglt2inhibitorsandthechanginglandscapefortreatmentofdiabetes AT wazira sglt2inhibitorsandthechanginglandscapefortreatmentofdiabetes AT cheemaan sglt2inhibitorsandthechanginglandscapefortreatmentofdiabetes
_version_	1718395286104047616

SGLT2 inhibitors and the changing landscape for treatment of diabetes

Ejemplares similares